Blog

Uma Borate: Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS?

Photo of Uma Borate from www.na.eventscloud.com

Apr 8, 2024, 15:14

Uma Borate: Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS?

Uma Borate, Acute Leukemia Translation Lead, Associate Professor at OHSU, shared on X:

“Fantastic start to ALFlive24 at Medscape LIVE with a clinically relevant debate amongst the greatest minds in MDS Rami Komrokji and Guillermo Garcia-Manero– Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS? What do you think ?- Vote”

Source: Uma Borate/X

Acute Leukemia Forum 2024 ALFlive24 cancer Guillermo Garcia-Manero Luspatercept MDS MedscapeLIVE myelodysplastic syndromes OHSU OncoDaily Oncology Oregon Health and Science University Rami Komrokji Uma Borate

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage